Performance Peak

Performance Peak is a research solution of five nitrogen-containing compounds: acetyl L-carnitine and carnitine at 200 mg each, agmatine and arginine at 50 mg each, and glutamine at 25 mg, listed at 525 mg/ml in total. Each component has its own research literature: glutamine as an inter-organ nitrogen carrier and glutaminase substrate, agmatine as an arginine-derived neuromodulator, arginine as the substrate of nitric oxide synthases, and carnitine and acetyl-L-carnitine in mitochondrial acyl transport and rat nerve-injury models. No study of the combination is cited. Lot data are on the certificate of analysis. It is sold strictly for laboratory research use.

Composition

• Glutamine 25mg
• Agmatine 50mg
• Arginine 50mg
• Acetyl L-Carnitine 200mg
• Carnitine 200mg
• 525MG/ML

Components

• Glutamine: L-glutamine. CAS 56-85-9; C₅H₁₀N₂O₃; 146.14 g/mol; PubChem CID 5961
• Agmatine: Agmatine (salt form not stated on the listing; free base shown). CAS 306-60-5; C₅H₁₄N₄; 130.19 g/mol; PubChem CID 199
• Arginine: L-arginine. CAS 74-79-3; C₆H₁₄N₄O₂; 174.20 g/mol; PubChem CID 6322
• Acetyl L-Carnitine: Acetyl-L-carnitine. CAS 3040-38-8; C₉H₁₇NO₄; 203.24 g/mol; PubChem CID 7045767
• Carnitine: L-carnitine (the listing does not state the isomer; data shown for L-carnitine). CAS 541-15-1; C₇H₁₅NO₃; 161.20 g/mol; PubChem CID 10917
• Form: Solution in a sealed vial, 525 mg/ml total as listed
• Analytical methods: Identity and purity data reported on the batch certificate of analysis

Research applications

• Glutamine: Reviewed as a carrier of nitrogen, carbon and energy between organs and as the substrate of liver-type and kidney-type glutaminase isoforms, which are regulated differently [1]
• Agmatine: Reviewed as an arginine decarboxylation product stored in synaptic vesicles, with affinity for α₂-adrenergic, imidazoline I₁ and NMDA receptors and inhibitory effects on nitric oxide synthase, studied mostly in rodent behavioral models [2]
• Arginine: Reviewed as the substrate that nitric oxide synthases oxidize to NO and L-citrulline, and for the competition between NOS and arginase for L-arginine [3]
• Acetyl-L-carnitine: A systematic review of rat sciatic nerve injury studies in which acetyl-L-carnitine was given in drinking water or intraperitoneally, covering thermal and mechanical thresholds, latency and apoptosis [4]
• Carnitine: Reviewed as a carrier of activated fatty acids and activated acetate across the inner mitochondrial membrane, synthesized from lysine-derived trimethyllysine [5]

Reference citations

1. Curthoys N.P. et al. (1995). Regulation of glutaminase activity and glutamine metabolism. Annu Rev Nutr, 15:133–159. PMID 8527215 · DOI
2. Halaris A. et al. (2007). Agmatine : metabolic pathway and spectrum of activity in brain. CNS Drugs, 21(11):885–900. PMID 17927294 · DOI
3. Boucher J.L. et al. (1999). Nitric oxide biosynthesis, nitric oxide synthase inhibitors and arginase competition for L-arginine utilization. Cell Mol Life Sci, 55(8-9):1015–1028. PMID 10484661 · DOI
4. Pourshahidi S. et al. (2023). The Effect of Acetyl-L-Carnitine (ALCAR) on Peripheral Nerve Regeneration in Animal Models: A Systematic Review. Neurochem Res, 48(8):2335–2344. PMID 37037995 · DOI
5. Bremer J. (1983). Carnitine–metabolism and functions. Physiol Rev, 63(4):1420–1480. PMID 6361812 · DOI

Compound data from PubChem CIDs 5961, 199, 6322, 7045767, 10917. Literature summaries describe published preclinical research and are not claims about this product’s effects in humans or animals.